University of Vermont

College of Medicine

Vermont Cancer Center

Bio for Mark K. Plante, MD, FRCS(C), FACS
Mark K. Plante, MD, FRCS(C), FACS

Mark K. Plante, MD, FRCS(C), FACS

Associate Professor and Chief
Division of Urology
Urology Residency Program Director
Associate Vice Chair, Research
Department of Surgery


Contact Information
E-mail: Mark.Plante@uvm.edu
Office Location:
FAHC - Urology / Surgery, ACC EP LVL 5

Education

M.D., McGill University, Montreal, Quebec, Canada, 1991
Residency in General Surgery, McGill University Teaching Hospitals, Montreal, QC,1991-1993
Residency in Urologic Surgery, McGill University Teaching Hospitals, Montreal, QC, 1993-1996

Academic Appointments

Associate Professor, Division of Urology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT 2007 - present
Assistant Professor, Division of Urology, Department of Surgery, College of Medicine, University of Vermont, Burlington, VT 1996 - 2006

Research Grants

“Hollow Fiber Catheter for Drug Delivery into the Prostate” – J. Stice, P. Zvara, M. Plante – co-investigators
 - NIDDK – SBIR – $397 414 total award (June 2010 – May 2011)

“The role of HVA alpha1E Ca2+ channel subunit in micturition reflex pathways” – K. Zvarova – principal investigator / G. Wellman, M. Nelson, M. Plante – co-mentors
 - NIDDK – K01 – $750 000 total award (Aug. 2008 – May 2013)

“Genetics of Androgen Receptor in Prostate Cancer: - C. Francklyn – principal investigator / M. Plante – collaborator
 - Vermont Cancer Center / LCCRO Pilot Research Award - $50 000 (2008)

 “Correlation of Urinary Bladder Afferent Activity and Function in Awake Mice” – P. Zvara – principal investigator / M. Plante, M. Nelson – collaborators
 - NIDDK – R29 – $418 000 total award (Sept. 2006 – Sept. 2008)

Publications

Patel SR, Hensle TW, Plante MK, Caldamone AA. John Kingsley Lattimer: Urologist, Ballistics Expert, and Historian. Urology. 2014 Jun 7. pii: S0090-4295(14)00371-9. doi: 10.1016/j.urology.2014.04.003. [Epub ahead of print]

Plante MK. Editorial comment. Urology. 2014 Mar;83(3):591.

Sarkissian H, Hardy S, Plante M, Mingin G. Pediatric Resident Exposure to Urology: Identifying a Need. J Urol. 2013;190(4 Suppl):1618-21.

Plante MK, Arscott WT, Folsom JB, Tighe SW, Dempsey RJ, Wesley UV. Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012 Sep 18. doi: 10.1038/pcan.2012.37. [Epub ahead of print]

King BJ, Plante MK, Kida M, Mann-Gow TK, Odland R, Zvara P. Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. J Urol. 2012;187(5):1898-902. Epub 2012 Mar 16.

Plante M, Wachterman J, Perrapato S. Options for the treatment of benign prostatic hyperplasia. Crit Rev Eukaryot Gene Expr. 2012;22(4):281-7.

Plante, M.  Editorial: Prospective Comparison of a New Visual Prostate Symptom Score Versus the International Prostate Symptom Score in Men with Lower Urinary Tract Symptoms. Urology 2011;78(1):17-20.

Woo H, Chin P, McNicholas T, Gill H, Plante M ,Bruskewitz R, Roehrborn C. Safety and Feasibility of the Prostatic Urethral Lift:  A Novel, Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. BJU Int 2011;108(1):82-8.

Capoliccchio JP, Saemi A, Trotter S, Plante M. Retroperitoneoscopic Nephrectomy with a Modified Hand-Assisted Approach. Urology, 2011;77:607-11.

Capoliccchio JP, Feifer A, Plante M, Tchervenkov J. Retroperitoneoscopic Living Donor Nephrectomy: Initial Experience with a Unique Hand-Assisted Approach. Clin Transplant, 2011;25:352-9.

Saemi A, Folsom J, Plante M. Injection Therapy for Prostatic Disease: A Renaissance Concept. Indian J Urol. 2008;24(3):329-35.

Saemi A, Plante M. Injectables in  the Prostate. Curr Opin Urol. 2008;18(1):28-33..

Plante M, Marks L, Anderson R, Amling C, Rukstalis D, Badlani G, Getlin L, Vang E. Phase I/II Trial to Examine the Safety of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia (IND #61337). J Urol, 2007;177:1030-35 (with video).

DiPaola R, Plante M, Kaufman H, Petrylak D, Israeli R, Lattime E, Manson K, Schuetz T. A Phase I Trial of Pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in Patients with Prostate Cancer. J Trans Med, 2006;4:1-5.